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Abstract 
Purpose: To construct a novel triple cell epitope-based polypeptide vaccine against cow mastitis 
induced by Staphylococcus aureus, Escherichia coli and Streptococcus and to reduce the use of 
antibiotics. 
Methods: Based on bioinformatics approach, a novel triple epitope-based polypeptide (CM-TEP) was 
designed and subjected to Ni-NTA flow resin purification. Purified CM-TEP was immunized into mice to 
prepare a polyclonal antibody. Pull-down assays and enzyme-linked immunosorbent assay (ELISA) 
were used to detect the interaction between CM-TEP antibodies and S. aureus, E. coli and 
Streptococcus. Active immunity mice and challenge of bacterial pathogens were used to detect immune 
protection of CM-TEP. Additionally, the optimal expressing conditions of CM-TEP strain were analyzed 
using orthogonal test design.   
Results: A novel cow mastitis triple cell epitope-based polypeptide (CM-TEP) with a MW of 36 kDa was 
designed, purified and used to immunize mice to prepare a polyclonal antibody. Pull-down assays and 
ELISA data showed that CM-TEP antibodies directly interacted with S. aureus, E. coli and 
Streptococcus. CM-TEP displayed a significant immune protective effect against infection by S. aureus 
(50 %, p < 0.05) and E. coli (54.54 %, p < 0.05) and provided some immune protective effect (30.78 %, 
p > 0.05) against Streptococcus. The optimum expressing conditions of CM-TEP were as follows: IPTG 
concentration of 0.3 mmol/L, strain OD600 value of 1, inducing temperature of 37 oC, and inducing time 
of 8 h. 
Conclusion: The findings suggest that epitope-based vaccine of CM-TEP may be a useful strategy for 
treating cow mastitis induced by S. aureus, E. coli and Streptococcus.   
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Cow mastitis is the most frequent and costly 
disease affecting dairy products worldwide [1], 
and its main pathogens include Staphylococcus 
aureus (S. aureus), Streptococcus and 
Escherichia coli (E. coli). At present, using 
antibiotics to treat mastitis can cause drug 
residues to be present in dairy products and can 
lead to the development of antibiotic resistance 
[2]. However, a single-dose vaccine that is 
effective against all three major bacterial 
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pathogens of cow mastitis has not been 
developed.  
 
Epitope vaccines are a new type of vaccines that 
have been developed in recent years. Compared 
with traditional vaccines, epitope vaccines can 
easily be recognized by major histocompatibility 
complex (MHC) molecules with different genetic 
backgrounds, and they have been studied for 
use against viruses and bacteria and in 
cancer immunotherapy [3,4]. To date, research 
has shown that many proteins are good 
candidates for mastitis vaccine, including 
clumping factor A (ClfA) and elastin binding 
protein (EbpS) of S. aureus [5,6], outer 
membrane protein C (OmpC) and outer 
membrane protein A (OmpA) of E. coli [7,8], and 
surface immunogenic protein (SIP) and 
phosphoglycerate kinase (PGK) of Streptococcus 
[9,10]. This study sought to construct and 
evaluate a novel triple-cell epitope-based vaccine 





Chemicals and reagents 
 
(HRP)-conjugated secondary antibodies, PBS 
and TMB were purchased from Sigma. Freund’s 
Complete Adjuvant and Freund’s Incomplete 
Adjuvant was purchased from Shanghai Sangon 
Biotech. Corp (Shanghai, China). CM-TEP 
nucleic acid sequences were synthesized and 
cloned in E. coli BL21 by the Shanghai Xuguan 




SPF Kunming mice (6 weeks old) were 
purchased from Xian Jiaotong University College 
of Medicine (Xian, China). All the animal 
experimental protocols were performed in 
accordance with the guidelines prescribed in 
Guide for the Care and Use of Laboratory 
Animals [11] and were approved by the Animal 
Ethical Committee (ref. no. 20150208), Shaanxi 




According to the amino acid sequence deposited 
in NCBI GenBank, the accession numbers of 
ClfA and EbpS proteins of S. aureus are 
EFM05894.1 and EFM06457.1, respectively; 
OmpC and OmpA of E. coli are AIL15476.1 and 
ELV73478.1, respectively; and SIP and PGK of 
Streptococcus are AEL21614.1 and 
AKU04271.1, respectively. 
 
Cell epitope analysis   
 
ABCpred (http://www.imtech.res.in/raghava/abcp 
red/ABC_submission.html) and the BepiPred 
1.0b (http://www.cbs.dtu.dk/services/BepiPred/) 
[12] software programs were used to predict the 
B cell epitopes of the proteins. nHLAPred 
(http://www.imtech.res.in/raghava/nhlapred/comp
.html) [3] and ProPred (http://www.imtech.res.in/ 
raghava/propred/) [4] were used to predict the 
cell epitope peptide segments of helper T cells 
(Th) and cytotoxic T lymphocytes (CTL), 
respectively. Four glycine residues (GGGG) were 
inserted into each epitope, and DNASTAR 
software was used to optimize the arrangement 
of the cell epitopes. The optimal antigenic 
combination was chosen as the final triple 
epitope polypeptide vaccine for cow mastitis 
(CM-TEP). The corresponding nucleic acid 
sequences were obtained by translation of the 
CM-TEP sequence. 
 
Prokaryotic expression, purification and 
antiserum preparation of CM-TEP  
 
CM-TEP nucleic acid sequences were 
synthesized and cloned in E. coli BL21 by the 
Shanghai Xuguan Biotech Development Corp., 
China. Prokaryotic expression and purification 
were performed as described previously [13]. 
Five-week-old Kunming mice were administered 
purified protein (100 μg per mouse) emulsified 
with Freund’s Complete Adjuvant (Shanghai 
Sangon Biotech. Corp., China), then given two 
injections of Freund’s Incomplete Adjuvant 
(Shanghai Sangon Biotech. Corp., China) at 
intervals of 14 days. Serum samples were 
collected from the mice and stored at −80 °C. 
 
Pull-down assays and ELISA to detect the 
interaction between CM-TEP antiserum and 
bacteria 
 
The bacterial pull-down assay was implemented 
as described previously [13]. Briefly, Bacterial 
cultures at OD600 1.0 were harvested by 
centrifugation, and the bacteria were washed 
with physiological saline (0.85 % NaCl). After the 
addition of 1 % oxymethylene (W/V) for 90 min at 
80 °C, the bacterial pellet was resuspended in 
physiological saline, and the final concentration 
was adjusted to 0.2 OD at 600 nm. One milliliter 
of bacterial suspension containing approximately 
108 CFU/mL bacterial cells was transferred into 
each 1.5-mL tube. After centrifugation, 100 μL of 
CM-TEP antiserum at various dilutions was 
added to the tubes and incubated for 1 h at 37 
°C. Additionally, 2 μg/μL BSA was used as the 
negative control. After being washed, the 
bacteria were combined with rabbit anti-mouse 
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secondary antibodies at a dilution of 1:3000 for 1 
h at 37 °C and washed again with PBS. After 
suspension of the bacteria in 20 μL of PBS, the 
samples were transferred to enzyme-labeled 
plates, and coloration liquid (50 μL of H2O2 and 
50 μL of TMB) was added to each well. Plates 
were maintained in the dark at 37 °C to allow the 
color reaction to develop. After 10 min, 50 μL of 
stop solution (2 M H2SO4) was added to each 
well, and the absorbance was read at 450 nm 
using a microplate reader (Bio-Rad, USA). 
 
Active immunity and challenge 
 
Mice were randomly divided into groups, and 
purified CM-TEP protein was intraperitoneally 
injected two times at an interval of 10 days, to 
deliver the primary and booster doses. Freund’s 
Complete Adjuvant and Freund’s Incomplete 
Adjuvant emulsified with CM-TEP protein (100 
μg per mouse) was utilized in the primary and 
booster immunizations, respectively. The control 
groups were immunized with Freund’s adjuvant. 
Immunized mice were intraperitoneally 
challenged with S. aureus, E. coli and 
Streptococcus at one week after the second 
immunization. Mice were observed for 15 days to 
measure their relative percentage survival (RPS). 




where Nt represents the vaccinated mortality in 
test group (triple epitope polypeptide vaccine of 
cow mastitis, CM-TEP), and Nc the non-
vaccinated mortality for control group. Statistical 
significance between groups was tested using 
SPSS software. 
 
Optimization of expression condition of CM-
TEP 
 
In order to optimize the expression conditions of 
CM-TEP protein, we have chosen orthogonal 
experiment design L9(34) [14], which is a four 
factors and three-level orthogonal design, and 
the factors are as follows: strain OD600 value (A), 
IPTG concentration (B), inducing time (C), and 
inducing temperature (D). In brief, according to 
L9(34) matrix mode, once the concentration of 
bacterial culture was reached, different 
concentrations of IPTG was added to the culture 
to induce protein production with 
appropriate temperature. Bacterial cells were 
harvested at the corresponding time based L9(34) 
matrix, heated for 5 min in boiling water and the 
proteins were electrophoresed by SDS-PAGE. 
The protein bands were visualized by staining 
with G-250. The optical density of CM-TEP 
protein bands was analyzed by Phoretix 1D 
software. Statistical analysis of the dataset was 
conducted using Statistical Package for the 
Social Science (SPSS) software. The experiment 




In silico prediction of B cell epitopes 
 
B cell epitopes of proteins were predicted by 
using the BepiPred 1.0b (Table 1) and ABCpred 
(Table 2) programs. On the basis of the common 
epitope sequence predicted by the two 
programs, the B cell epitope segment of S. 
aureus ClfA protein was at residues 114 – 129 
and 326 – 330, and that of the Ebps protein was 
at residues 87 – 102 and 132 – 147. The B cell 
epitope segment of E. coli OmpA protein was at 
residues 44 – 50 and 126 – 135, and that of the 
OmpC protein was at residues 19 – 31 and 129 – 
144. The B cell epitope segment of 
Streptococcus SIP protein was at residues 224 – 
238 and 346 – 358, and that of the PGK protein 
was at residues 64 – 79 and 324 – 329. 
 
In silico prediction of CTL cell epitopes 
 
On the basis of the nHLAPred method, the CTL 
cell epitope segment of Ebps and ClfA protein 
was at residues 318 – 326 and 895 – 902, 
respectively; the OmpA and OmpC of E. coli 
were at residues 237 – 245 and 295 – 303, 
respectively; and the Streptococcus PGK protein 
was at resides 73 – 81, but the SIP protein did 
not display a CTL cell epitope (Table 3). 
 
Table 1: Identification of B cell epitopes for proteins by 
using the BepiPred 1.0b method 
 
Protein 
name Peptide segment position 
Ebps 6-60, 69-121, 127-318, 346-446, 457-467, 
473-481 
ClfA 34-203, 205-211, 223-234, 242-254, 264-
272, 288-299, 323-330, 338-347, 355-362, 
385-394, 399-407, 415-428, 464-484， 
OmpA 19-30, 44-59, 61-67, 83-95, 126-145, 165-
181 
OmpC 19-31, 46-55, 64-93, 129-144, 170-212, 
221-252, 264-270, 277-283, 315-321 
SIP 23-35, 45-56, 97-104, 107-125, 144-154, 
160-169, 179-216, 218-238, 242-249, 253-
288, 290-325, 334-342, 346-358, 375-384, 
402-423 
PGK 64-76, 120-136, 188-194, 269-277, 280-
290, 324-334, 344-359 
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Table 2: Identified B cell epitopes for proteins based 
on ABCpred method 
 
Protein 








In silico prediction of Th cell epitopes 
 
Using the ProPred method, we predicted the Th 
epitopes of the six proteins (Table 4). Th cell 
epitopes segments of S. aureus Ebps and ClfA 
protein were at residues 479 – 487 and 201 – 
209, respectively; the OmpA and OmpC protein 
of E. coli were at residues 284 – 292 and 6 – 12, 
respectively; and the PGK and SIP protein of 
Streptococcus were at residues 317 – 325 and 
240 – 248, respectively. 
 
Reorganization of series epitopes 
 
Different possible arrangement and combinations 
of epitopes were optimized by using DNAStar 
software (Figure 1), and the final amino acid 














Table 3: Identified CTL epitopes for proteins 
 
Protein name Rank Type Peptide segment position 
EbpS 1 HLA-A2 119-127，318-330，337-345 
2 HLA-A*0201 318-330 
3 HLA-A*0202 318-330 
4 HLA-A*0203 318-326 
5 HLA-A*0205 269-277，318-331，332-340 
ClfA 1 HLA-A2 504-512，894-902 
2 HLA-A*0201 895-903 
3 HLA-A*0202 895-903 
4 HLA-A*0203 121-129，290-296，297-305，425-433，895-903 
5 HLA-A*0205 220-228，353-361，406-141，538-546，891-899 
OmpA 1 HLA-A2 117-125，181-189，237-245 
2 HLA-A*0201 237-248 
3 HLA-A*0202 237-245 
4 HLA-A*0203 11-19，100-108 
5 HLA-A*0205 11-18，19-27，55-63，92-99，100-108，110-116，117-125，
152-160，209-217，222-230，237-245 
OmpC 1 HLA-A2 7-15，73-81，113-121，258-266，295-303 
2 HLA-A*0201 7-15，295-303 
3 HLA-A*0202 7-15，197-205，295-303 
4 HLA-A*0203 258-266，288-296 
5 HLA-A*0205 33-41，97-105，295-303，322-330，353-361 
SIP 1 HLA-A2 ------ 
2 HLA-A*0201 12-20，67-75 
3 HLA-A*0202 226-234 
4 HLA-A*0203 2-10，147-155，254-262 
5 HLA-A*0205 9-17，53-61，67-75，85-93，132-140，151-159，160-168，
184-192，229-237，269-277，298-306，316-324，356-364 
PGK 1 HLA-A2 55-63 
2 HLA-A*0201 16-24，73-81，99-105，106-114，134-142 
3 HLA-A*0202 16-24，55-63，73-81，99-107，161-169，260-268，310-318 
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Table 4: Identified Th epitopes for proteins 
 
































































Figure 1: Antigenic index of the CM-TEP. The predicted epitopes were connected by GGGG flexible regions, 
thus making them independent of each other 
 
Prokaryotic expression, purification and 
immunogenicity analysis of CM-TEP  
 
Heterologous expression of CM-TEP in E. coli 
and induction with IPTG resulted in the 
production of a protein of approximately 56 kDa 
in size, which corresponded to a fusion protein of 
20.4 kDa and CM-TEP of 36 kDa (Figure 2). This 
was the expected size of the recombinant 
protein. A reasonable quantity of CM-TEP was 
purified by Ni-NTA super flow resin (Figure 2 and 
Figure 3). Purified CM-TEP was used to 
immunize mice to prepare a polyclonal antibody. 
Pull-down and ELISA results showed that the OD 
450nm value decreased as the CM-TEP antiserum 
dilution increased and was near to zero in the 
control serum (Figure 3). These data indicated a 
direct interaction between CM-TEP antiserum 
and S. aureus, E. coli and Streptococcus. 
 
Liu et al 




Figure 2: Expression and purification of CM-TEP. M, 
protein marker. 1, non-induced strain. 2, IPTG-induced 
strain. 3, purified CM-TEP. Heterologous expression of 
CM-TEP in E. coli and induction with IPTG resulted in 
the production of a protein of approximately 56 kDa in 
size, including a fusion protein of 20.4 kDa and CM-
TEP of 36 kDa. This was the expected size of the 
recombinant protein. A reasonable quantity of CM-
TEP was purified using Ni-NTA super flow resin and 
produced only one band 
 
CM-TEP immune protective  
 
An active immunization approach was used to 
investigate the ability of CM-TEP to protect mice 
against infection. After infection with S. aureus, 
E. coli and Streptococcus, the mice showed 
severe symptoms. Many of the mice died, but 
those that survived were able to gradually 
resume activities after 4 days. Compared with 
the control group of Freund’s immunized 
adjuvant, the CM-TEP group displayed a 
significant immune protective effect against 
infection by S. aureus (50 %, p < 0.05) and E. 
coli (54.54 %, P < 0.05) and provided some 
immune protection against Streptococcus (30.78 
%, p > 0.05) (Table 5). 
 
Optimization of expression condition of CM-
TEP expression strain 
 
Based on orthogonal design and SDS-PAGE 
electrophoresis, the expression of CM-TEP was 
shown in Figure 4. Optical density value of CM-
TEP bands was analyzed by Phoretix 1D 
software (Table 5). By comparing the K1, K2 and 
K3 in Table 5, the optimal expression condition of 
CM-TEP was A3, B2, C2 and D3, which meant 
strain OD600 value of 1, IPTG concentration of 
0.3 mmol/L, inducing time of 8 h and inducing 
temperature of 37 oC, respectively. Range 
analysis showed that the influence degree of 
each factors on the expression of CM-TEP was 
C > B > D > A (Table 6).  For CM-TEP 
expressing, notable statistical significance of 
factors were IPTG concentration, inducing time 






Figure 3: The interaction between CM-TEP antiserum 
and the three bacterial pathogens, as determined by 
ELISA. A, B and C were CM-TEP antiserum 
interaction with S. aureus, E. coli and Streptococcus, 
respectively. The OD450 value decreased as the serum 
dilution increased and was almost zero in control 
serum 
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Figure 4: Inducing expressing of CM-TEP expression 
strain. M: Protein marker. 1, non-induced strain. 2 – 4: 
strain OD600 value of 0.5, IPTG concentration of 0.1, 
0.3 and 0.5 mmol/L, inducing time was 3, 8 and 12 h, 
and inducing temperature: 28, 32 and 37 ℃. 5 – 7: 
strain OD600 value of 0.8, IPTG concentration of 0.1, 
0.3 and 0.5 mmol/L, inducing time: 8, 12 and 3 h, and 
inducing temperature: 32, 28 and 37 oC. 8 – 10: strain 
OD600 value of 1, IPTG concentration of 0.1, 0.3 and 
0.5 mmol/L, inducing time: 12, 3 and 8 h, and inducing 




There are many methods available for predicting 
B cell epitopes, including BepiPred, ABCpred 
and BPAP [15]. Through BepiPred and ABCpred, 
the B cell epitopes were predicted for membrane-
associated proteins of C. jejuni [12] and Gly m 
Bd 28K of soybean allergens [16]. This study 
used a combination of the BepiPred and 
ABCpred methods to improve the prediction 
accuracy of the B cell epitope for the six proteins. 
 
CTL cell epitopes play an integral role in the 
adaptive immune response by recognizing 
peptides combine to major histocompatibility 
complex class I (MHC-I) molecules; the 
prediction methods include nHLAPred, IEDB, 
SYFPEITHI and IMTECH [17]. The nHLAPred 
method has been used to predict CTL cell 
epitopes for Leishmania major-related candidate 
antigens and HIV Gag protein [3]. We used the 
same method to identify a novel critical epitope, 
which may play a major role in activating CD8+T 
cells [3], thereby increasing the development of 
immunogenicity.  
 
The ProPred method was found to be efficient for 
the Th epitope prediction of bacteria [4] and viral 
proteins [18]. In this article, we used the ProPred 
method to obtain protein Th epitopes, which 
could be combined with MHC-II molecules to 
enhance the immune response. 
 
The flexible portions are underlined. Epitope 
joints can be divided into flexible and rigid, and 
frequently used amino acid connection joints 
sequences are GGGG, AAY, KK and GGGGS 
[19]. DNAStar software can be used to 
recombine epitopes for optimal antigenicity [20]. 
We used the GGGG amino acid joint and used 
DNAStar software to optimize different epitopes 
to obtain a polypeptide (CM-TEP) with optimal 
antigenicity. 
 
The cow mastitis researchers have found that 
recombinant epitope (Sip-ClfA) antiserum 
capacities for opsonizing, adhesion and 
phagocytosis are significantly greater than those 
of the killed bacteria after immunization, and that 
these recombinant epitopes also exhibit good 
immunogenicity [21]. This study indicated a direct 
interaction between CM-TEP antiserum and S. 
aureus, E. coli and Streptococcus. Thus, CM-
TEP was expected to have good 
immunogenicity. Additionally, several studies 
have found that immunization with the B cell 
epitope (Sip-ClfA) provides better protection 
against both S. agalactiae and S. aureus 
challenges [21]. In this study, CM-TEP 
immunization developed an immune protection 
against all three major bacterial pathogens of 
cow mastitis. Thus, CM-TEP is expected to be an 
approach to the development of a vaccine 
against cow mastitis.  
 
In order to apply to industrial production, the 
optimum expression conditions were studied to 
obtain abundant and high quality of CM-TEP, 
which were strain OD600 value of 1, IPTG 
concentration of 0.3 mmol/L, inducing time of 8 h 
and inducing temperature of 37 ℃, respectively. 
IPTG is toxic [22] and should be induced by low 
concentration in practical production, and the 
same to our research. In addition, the suitable 
induction time is favorable to the synthesis of 
protein  [23],  and  the  production  cost  can  be  
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80 / − / − 73.33 / − / − 86.67 / − / − 
ADR, accumulating death rates. RPS (%) = 1 − (% vaccinated mortality/% non-vaccinated mortality) × 100. Sig., 
significance. * p < 0.05 (compared with control). CM-TEP displayed a significant immune protective effect against 
the infection of S. aureus (50 %, p < 0.05) and E. coli (54.54 %, p < 0.05), and displayed some immune 
protection against Streptococcus (30.78 %, p > 0.05) 
 
  Table 6: Inducing expression condition of CM-TEP strain 
 
Number A B (mmol/L) C (h) D (℃) Optical density/SD (×105) 
1 (A1B1C1D1) 0.5 0.1 3 28 1.552 ± 0.026 
2 (A1B2C2D2) 0.5 0.3 8 32 2.325 ± 0.144 
3 (A1B3C3D3) 0.5 0.5 12 37 2.102 ± 0.184 
4 (A2B1C2D3) 0.8 0.1 8 37 2.777 ± 0.283 
5 (A2B2C3D1) 0.8 0.3 12 28 2.840 ± 0.082 
6 (A2B3C1D2) 0.8 0.5 3 32 0.601 ± 0.173 
7 (A3B1C3D2) 1.0 0.1 12 32 2.218 ± 0.194 
8 (A3B2C1D3) 1.0 0.3 3 37 2.052 ± 0.100 
9 (A3B3C2D1) 1.0 0.5 8 28 2.338 ± 0.271 
K1 (Mean value 1) 1.993  2.182  1.401  2.243   
K2 (Mean value 2) 2.073  2.406  2.480  1.715   
K3 (Mean value 3) 2.203  1.681  2.387  2.310   
Range analysis 0.210  0.725  1.079  0.595   
The factor of A, B, C, and D means strain OD600 value, IPTG concentration, inducing time and inducing 
temperature, respectively. By comparing the data size of K1, K2 and K3, the optimal expression condition of CM-
TEP was A3, B2, C2 and D3. Range analysis showed that the influence degree of each factors on the expression 
of CM-TEP was C > B > D > A 
 
Table 7: Variance results for CM-TEP expressing 
 
Factor Optical density value analysis 
Mean square F value P value 
A 0.101 3.096 0.070 
B 1.241 38.109 0.000 
C 3.215 98.738 0.000 
D 0.957 29.406 0.000 
The factor of A, B, C, and D means strain OD600 value, 
IPTG concentration, inducing time and inducing 
temperature, respectively. P < 0.05 means the 
difference with control group is significant 
 
saved compared with the blind setting time. 




A novel triple-cell epitope-based polypeptide 
(CM-TEP) has been designed, optimized 
expression. It displays a significant immune 
protective effect against the infection of S. 
aureus and E. coli while providing some immune 
protection against Streptococcus. Thus, a new 
member has been added to the group of triple 
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